NCT03127007View on ClinicalTrials.gov

Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

April 27, 2017

Primary Completion Date

February 22, 2024

Study Completion Date

October 15, 2024

Conditions
Rectal Neoplasms
Interventions
DRUG

Atezolizumab

Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.

DRUG

5-FU based radio-chemotherapy

IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.

Trial Locations (5)

1000

Institut Jules Bordet, Brussels

1070

Hôpital Erasme, Brussels

1320

Cliniques universitaires St Luc, Brussels

3000

Katholiek universiteit Leuven, Leuven

6000

GHdC, Charleroi

All Listed Sponsors
collaborator

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

lead

Grand Hôpital de Charleroi

OTHER

NCT03127007 - Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer | Biotech Hunter | Biotech Hunter